findmyKOL
Clinical trialNCT05654506RecruitingPhase 2Interventional

Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

SponsorMayo ClinicEnrollment40Proliferative Glomerulonephritis With Monoclonal IgG Deposits
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic

    Jacksonville, Florida, United States

    Nabeel Aslam, MD
    Recruiting
  • Mayo Clinic

    Rochester, Minnesota, United States

    Fernando Fervenza, MD →Ladan Zand, MD
    Recruiting
  • University North Carolina at Chapel Hill

    Chapel Hill, North Carolina, United States

    Patrick Taus, MD
    Recruiting
  • Oregon Health and Science University

    Portland, Oregon, United States

    Rupali Avasare, MD
    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Daratumumab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Aug 2023
Primary completion
31 Aug 2026
Completion
31 Aug 2026
Last update posted
16 Sept 2025
Registered enrollment
40
Registry id
NCT05654506
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.